Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 308Lung Neoplasms 70Neoplasms 50Neoplasm Metastasis 33Parkinson Disease 4, Autosomal Dominant Lewy Body 20Colorectal Neoplasms 20Carcinoma 20Mesothelioma 15Breast Neoplasms 15Mesothelioma, Malignant 13Small Cell Lung Carcinoma 11Melanoma 10Adenocarcinoma 10Neoplasms by Site 9Adenocarcinoma of Lung 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Lung Diseases 7Thoracic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Non-Squamous Non-Small Cell Lung Cancer 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Respiratory Tract Diseases 5Recurrence 5Rectal Neoplasms 5Neoplasms by Histologic Type 5NSCLC 5Head and Neck Neoplasms 5Endometrial Neoplasms 5

Interventions

Irinotecan 5Bevacizumab 5Leucovorin 4Fluorouracil 45,10-methylenetetrahydrofolic acid 3Oxaliplatin 2Levoleucovorin 2Drug Therapy 2Cetuximab 2trametinib 1spartalizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1nazartinib 1napabucasin 1encorafenib 1canakinumab 1alectinib 1Tinzaparin 1Radiotherapy 1Pemetrexed 1Ocoxin 1Mass Screening 1KRN-330 1Folfox protocol 1Capecitabine 1Artesunate 1ABT-165 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Intestinal Neoplasms × Pemetrexed × Clear all
NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Isofol Medical AB

Phase 1/2 Completed
24 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡